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In this editorial we traverse the continuum of 
transmission of HIV-1 from mothers to children to 
highlight the biomedical history of this problem. 
Treatment has progressed from prevention with 
antiretrovirals (ARVs) through to a broader set of 
interventions, including various breastfeeding options and other health 
system improvements, that have increased the possibility of eliminating 
mother-to-child-transmission (MTCT) of HIV. At the far end of the 
continuum, the spectacular findings in the case of the Mississippi 
‘cured’ baby indicate that eradication is possible.
HIV infections in children are overwhelmingly due to MTCT,[1] intra-
uterine infections accounting for 10 - 25% of cases and intrapartum 
infections and those through breastfeeding for 35 - 40%. High- and 
middle-income countries have had considerable success in preventing 
new HIV infections in children. All HIV-positive pregnant women 
in developed countries are treated with ARVs, so they have low viral 
loads (VLs) before and during delivery. In Europe and the USA, 
perinatal HIV-1 transmission occurs in only 1% of treated women 
with RNA virus loads <1  000 copies/ml. With further suppression of 
viraemia, perinatal transmission may be eliminated.[2] The World Health 
Organization (WHO) uses standardised transmission rates:[3] the 2010 
WHO-recommended regimens (options A or B) are estimated to be 
associated with a 2% probability of peripartum transmission and a 0.2% 
probability of transmission per month of breastfeeding. Peripartum and 
postnatal transmission probabilities were lowest for women who were 
taking antiretroviral therapy (ART) before the pregnancy, namely 0.5% 
peripartum and 0.16% per month of breastfeeding.
Intra-uterine and intrapartum transmissions account for the majority 
of transmissions in industrialised countries, whereas in developing 
countries breastfeeding (up to 24 months of age) can account for 
30 - 40% of all MTCT.[1,4] Interventions directed at all three routes of 
transmission have been very successful in industrialised countries, where 
transmission rates have fallen from ~25% to <2% and survival of infants 
has improved.[4] In many middle-income countries transmission rates 
are now ~2 - 3%. In South Africa (SA), anecdotal data suggest that the 
transmission rate in the early 1990s was ~32%. It was 2.5% in 2012.[5]
Summarising evidence for three levels of avoiding MTCT, we examine 
the experience of preventing MTCT globally, and suggest the probability 
of eliminating transmission, especially in South Africa (SA). Finally, 
we raise the question of eradicating new HIV infections in children 
altogether. Elimination and eradication are defined in Table 1.
We stress that much of the hard scientific data on prevention 
and elimination are already available; what is required are health 
service refinements. Eradication demands many more basic science 
experiments to confirm the results indicating ‘cure’ in the Mississippi 
baby, and to increase our understanding of the biology of latency 
and destruction of the replicative capacity of the virus. We need 
more information on the cellular and molecular environment of 
the CD4+ memory cells, and specific sites that harbour the virus. 
Among the prerequisites for eradication are public health studies 
to enable SA to scale up facilities and personnel for very early 
diagnosis and treatment.
Prevention
Numerous reviews of trials undertaken to prevent MTCT have 
demonstrated the efficacy of a number of interventions. In brief, 
these include ARVs, exclusive breastfeeding, and various health 
service measures such as ‘baby-friendly hospitals’.[1,4,6,7] The WHO 
has consolidated these data.[8,9] In 2010, deaths attributable to 
breastfeeding risk factors remained fairly high globally, suboptimal 
breastfeeding, for example, accounting for deaths of 293 449 male and 
251  368 female infants.[10,11] Figures for discontinued breastfeeding 
and non-exclusive breastfeeding are similar.[11]
A set of ‘four prongs’ as a framework to prevent MTCT of 
HIV-1 has been recommended by the WHO to tackle the problem 
comprehensively, and is critical in devising an effective and holistic 
approach to MTCT. [12] Their implementation is key to both elimination 
of MTCT and eradication of HIV in children. The first prong aims at 
prevention of HIV in women, the second at prevention of unintended 
pregnancies in HIV-infected women, the third at prevention of 
transmission of the virus from mothers to their babies, and the fourth 
at care and support for HIV-infected women, their infants and their 
families. As part of the general progress in HIV health services in SA 
(see below), for example, the unmet need for family planning (i.e. the 
second prong) is <5%.[13,14]
SA has made considerable progress in confronting and driving 
back HIV-1.[5] The government has launched an HIV counselling 
and testing campaign to reach 16 million people, rapidly expanded 
circumcision rollout, enhanced prevention of mother-to-child 
transmission (PMTCT) programmes, promoted integration of the 
treatment of HIV and tuberculosis, and drastically increased its budget 
to expand ART to 1.7 million people while simultaneously moving 
thousands of patients from PEPFAR-funded treatment programmes 
to government services. The impact of PMTCT programmes in SA 
is now evident at community level. Within 10 years of the start of 
the country’s PMTCT programme, 95% of all health facilities were 
providing this service in 2010. SA is also one of four countries that 
have achieved over 80% coverage with ARV prophylaxis to prevent 
MTCT. More than 98% of women receive an HIV test during 
pregnancy, and 91.7% of HIV-positive mothers are receiving ART or 
prophylaxis.[14] The national survey in SA[5] showed that MTCT rates 
had fallen to ~2.7% (95% confidence interval 2.1 - 3.2%) in 2011. This 
was confirmed by recently published global reports[13,14] revealing that 
new HIV infections in SA children (aged 0 - 14 years) have continued 
to decline, with a fall of 63% (from 38 000 to 14 000) between 2009 
and 2012. Furthermore, 70% of eligible children are receiving ARVs. 
Transmission rates have fallen throughout the world, including SA, as 
coverage of MTCT services has increased to nearly 90%.[5]
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Table 1. Definitions of outcomes in HIV infection 
Maternal disease 
progression
Death, WHO stage 4, or CD4+ count 
<200 cells/µl
Elimination Absence of clinical signs + undetectable viral 
particles (in blood and other tissues), without 
ARV use in a patient previously diagnosed 
and treated for HIV; MTCT rate <5%
Eradication Elimination + absence of virus in previously 
infected latent memory cells; MTCT rate <2%
Amelioration Substantial improvement of clinical signs and 
stable viral load in blood
WHO = World Health Organization; ARV = antiretroviral;   
MTCT = mother-to-child transmission.
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SA’s success in dealing with MTCT has been made possible by 
sound leadership, investments in infrastructure involving personnel, 
facilities and resources, and wider coverage of PMTCT programmes. 
In 2009 - 2013, 9 out of every 10 HIV-infected pregnant women 
received ARVs for PMTCT and 9 out of every 10 infants received 
ARVs to prevent breastfeeding transmission.[14] At the time of writing, 
there is universal access to ARVs, with 80% of eligible pregnant 
women receiving ART for their own health.
Elimination
We have recently drawn together health service changes that will be 
instrumental in eliminating MTCT.[15] In essence, elimination requires 
escalation, intensification and improvement of the components of 
the WHO ‘four prongs’ approach described above. In particular, 
differential coverage of health services in developing countries has 
hindered progress, so PMTCT services ought to form part of universal 
coverage, and the gender-related interventions – primary prevention 
of HIV in women, family planning counselling, and voluntary and 
informed termination of unwanted pregnancies – should be integrated 
into comprehensive PMTCT programmes. Improved advocacy, 
information and guidance are required to increase public demand 
and use of these services. Within countries, implementation of recent 
WHO/UNAIDS ARV Guidelines,[16] promotion of breastfeeding and 
prevention of breastfeeding transmission, and continuing care of 
mothers and children are necessary.
Eradication
The news from a highly reputable group of researchers that a baby 
in Mississippi had been cured of HIV infection was greeted by 
widespread astonishment, clamorous voices of approval, unrestrained 
cries of delight and a storm of doubt. For more than 30 years the 
HIV epidemic has dominated our science and threatened our lives 
and health, the gloom brigade even questioning our survival. Cure 
seemed a distant yet ultimate goal – the ‘holy grail’ of modern 
scientific endeavour. And here was the first glimmer of a solution.
The mother presented in labour, so no ARVs were given before 
or during labour. The premature baby was HIV RNA- and DNA-
positive, but the VL was moderate when blood samples were tested 
at 30 and 31  h. Samples from Mississippi were transported to a 
specialised laboratory, and in utero HIV infection was diagnosed. 
The virus isolated from the mother was replication competent and 
behaved like other wild-type or laboratory isolates, and neither 
mother nor baby had genetic markers typical of elite controllers. 
Mother and baby were started on ARVs ~30 h before the diagnosis 
was known, with tests showing a decreasing VL over the baby’s first 
month of life. Mother and baby were lost to follow-up (but the infant 
may have received 12 - 15 months of ART). The mother returned after 
2 years, with her baby clinically well, not on ARVs, and seronegative. 
No HIV was identified by standard tests, but more sophisticated tests 
showed HIV DNA sequences of uncertain significance on occasional 
peripheral white blood cells.
The priority research questions were soon established by experts. 
For example, the currently available ARVs are not all suited for 
newborns, so an urgent priority is to work with pharmaceutical 
manufacturers to define the most useful formulations and to provide 
existing zidovudine/lamivudine dispersible tablets with score marks 
to allow them to be broken into quadrants of 15/7.5 mg. Some of us 
believed that the most suitable country to do the studies required to 
confirm and extend the findings was SA – and in fact the purpose 
of a recent symposium[17] was to report on ‘Scientific advances from 
the “Mississippi baby”: Implications for public health programmes 
on MTCT of HIV’. There are 12 recommendations, covering a 
broad range of fields.[4,18] Some of the public health proposals were 
to improve health services as laid out in recent WHO documents 
on elimination of MTCT, and more aggressive management of HIV-
exposed newborns. Challenges identified were diagnosis of HIV 
at birth, logistical constraints in testing HIV-exposed newborns, 
availability of the technology for diagnosis, encompassing better 
point-of-care tests, and appropriate ART for newborns.
A suggested package of interventions to ‘eradicate’ MTCT in 
South Africa includes optimising implementation of the evidence-
based WHO ‘four prongs’ comprehensive strategy for PMTCT, 
improved health services, especially during the perinatal period, 
infancy and childhood, specifically addressing measures to reduce 
under-5 and maternal mortality, and improved diagnostic and 
therapeutic options.
Additional evidence of ‘cures’
• The first and only reported case of a sterilising cure was Timothy 
Brown, the ‘Berlin patient’, who was HIV-infected and was given a 
bone marrow transplant for acute myeloid leukaemia. The donor was 
naturally resistant to HIV due to a mutation in the CCR5 gene, a critical 
protein required by HIV to enter and infect cells. Brown stopped ART 
very soon after transplantation and remains free of HIV after 6 years.[19]
• A French report (Visconti cohort) suggests that HIV has been 
eliminated in adults with chronic infection. This group of patients 
started treatment within 10 weeks of being infected and adhered 
to a course of ARV drugs for 3 years, on average, but then stopped. 
Some have remained under control for a decade.[20]
• So-called ‘elite controllers’, who have undetectable VLs in the 
absence of ARVs, have been recognised for some time.[21]
A Ramkissoon
H Coovadia
Maternal, Adolescent and Child Health, Department of Obstetrics 
and Gynaecology, Faculty of Health Sciences, University of the 
Witwatersrand, Johannesburg, South Africa
Corresponding author: H Coovadia (hcoovadia@match.org.za)
1. Coovadia HM, Newell ML. Effective HIV prevention and treatment for pregnant mothers. Meeting 
health care needs. In: Heyman J, Sherr L, Kidman R, eds. Protecting Childhood in the AIDS 
Pandemic: Finding Solutions that Work. New York: Oxford University Press, 2012:169-194.
2. Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus 
type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis 2001;183(4):539-545. 
[http://dx.doi.org/10.1086/318530]
3. Rollins N, Mahy M, Becquet R, Kuhn L, Creek T, Mofenson L. Estimates of peripartum and 
postnatal mother-to-child transmission probabilities of HIV for use in Spectrum and other 
population-based models. Sex Transm Infect 2012;88(suppl 2):i44-i51. [http://dx.doi.org/10.1136/
sextrans-2012-050709]
4. Rollins N, Coovadia HM. Breastfeeding and HIV transmission in the developing world: 
Past, present, future. Curr Opin HIV AIDS 2013;8(5):467-473. [http://dx.doi.org/10.1097/
COH.0b013e3283632ba2]
5. Goga AE, Dinh TH, Jackson DJ; for the SAPMTCTE study group. Evaluation of the Effectiveness of the 
National Prevention of Mother-to-Child Transmission (PMTCT) Programme Measured at Six Weeks 
Postpartum in South Africa, 2010. South African Medical Research Council, National Department 
of Health of South Africa and PEPFAR/US Centers for Disease Control and Prevention, 2012. 
http://repository.uwc.ac.za/xmlui/bitstream/handle/10566/462/GogaPMTCT2012.pdf?sequence=3 
(accessed 5 November 2013).
6. Townsend CL, Cortina-Boria M, Peckham CS, et al. Low rates of mother to child transmission of 
HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. 
AIDS 2008;22(8):973-981. [http://dx.doi.org/10.1097/QAD.0b013e3282f9b67a]
7. Pérez-Escamilla R. Evidence based breast-feeding promotion: The Baby-Friendly Hospital Initiative. 
J Nutr 2007;137(2):484-487.
8. World Health Organization. Rapid Advice: Use of antiretroviral drugs for treating pregnant women 
and preventing HIV infection in infants. November 2009. http://www.who.int/hiv/topics/mtct/ 
(accessed 15 June 2010).
9. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing 
HIV Infection in Infants: Towards Universal Access. Recommendations for a Public Health 
Approach (2010 version). 2010. http://www.who.int/hiv/pub/mtct/antiretroviral2010/en/index.
html (accessed 15 November 2010).
10. Lozano R, Naghavi M , Foreman K, et al. Global and regional mortality from 235 causes of death for 
20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study. Lancet 
2013;380(9859):2095-2128. [http://dx.doi.org/10.1016/S0140-6736(12)61728-0]
EDITORIAL
20       January 2014, Vol. 104, No. 1
11. Lim SS, Vos TP, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury 
attributable to 67 risk factors and risk factor clusters in 21 regions, 1990 - 2010: A systematic analysis 
for the Global Burden of Disease Study 2010. Lancet 2013;380(9859):2224-2260. [http://dx.doi.
org/10.1016/S0140-6736(12)61766-8]
12. Sweat MD, Reilly KR, Schmidt GP, et al. Cost-effectiveness of nevirapine to prevent mother to
child HIV transmission in eight African countries. AIDS 2004;18(12):1661-1671. [http://dx.doi.
org/10.1097/01.aids.0000131353.06784.8f]
13. World Health Organization. Programmatic Update. Use of Antiretroviral Drugs for Treating
Pregnant Women and Preventing HIV Infection in Infants. Executive Summary April 2012.
Geneva: WHO, 2012. http://whqlibdoc.who.int/hq/2012/WHO_HIV_2012.6_eng.pdf (accessed 21 
September 2013).
14. World Health Organization. 2013 Progress Report on the Global Plan Towards the Elimination of 
New HIV Infections among Children by 2015 and Keeping Their Mothers Alive. Geneva: WHO/
UNAIDS, 2013. http://www.unaids.org/en/.../2013/20130625_progress_global_plan_en.pdf (accessed 
1 September 2013).
15. Coovadia HM, Govender T. Eliminating mother to child transmission of HIV-1 and keeping mothers 
alive: Recent progress. J Infect 2013 (in press). [http://dx.doi.org/10.1016/j.jinf.2013.09.015]
16. World Health Organization. HIV/AIDS Programme. Consolidated Guidelines on the Use of
Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public 
Health Approach. Geneva: WHO, 2013.
17. UNAIDS/CAPRISA. Report on the UNAIDS Symposium on the scientific advances from the
‘Mississippi baby’ and the implications for public health programmes to eliminate mother-to-child-
transmission of HIV, 3 - 4 June 2013, Durban, South Africa. https://www.facebook.com/permalink.
php?id=327735533989998 (accessed 22 September 2013).
18. UNAIDS. 12 recommendations following a discussion about the ‘Mississippi baby’. http://www.
unaids.org/en/resources/documents/2013 (accessed 12 September 2013).
19. Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially
curative interventions: A study of the Berlin patient. PLoS Pathog 2013;9(5):e1003347. [http://
dx.doi.org/10.1371/journal.ppat.1003347]
20.  Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term 
virological remission after the interruption of early initiated antiretroviral therapy. ANRS VISCONTI 
Study. PLoS Pathog 2013;9(3):e1003211. [http://dx.doi.org/10.1371/journal.ppat.1003211]
21. Deeks SG, Walker BD. Human immunodeficiency virus controllers: Mechanisms of durable virus 
control in the absence of antiretroviral therapy. Immunity 2007;27(3):406-416. [http://dx.doi.
org/10.1016/j.immuni.2007.08.010]
S Afr Med J 2014;104(1):18-20. DOI:10.7196/SAMJ.7603
